It is the top of the page

Link for moving within the page
To text (c)



April 2021

Establishment of ZENOAQ HOLDINGS CO., LTD.
The veterinary pharmaceutical company Nippon Zenyaku Kogyo Co., LTD., and the human pharmaceutical company ZENOAQ Resource Co., LTD. (now ZENOGEN Pharma Co., LTD.) became wholly owned subsidiaries of ZENOAQ HOLDINGS CO., LTD.


March 2019

Appointment as a Corporate Member of HealthforAnimals.

October 2018

Establishment of the New York Branch Office in the U.S.A.

May 2018

Appointment of Mr. Toshikazu Fukui as President.

December 2017

Winner of the Fukushima Industry Award 2017.

November 2017

Completion of the construction of the new quality control center in Koriyama, Japan.

November 2016

Winner of the Japan Quality Award 2016.

January 2016

Establishment of Vetoquinol-Zenoaq K.K., a joint venture with Vetoquinol SA.

July 2015

Research and development collaboration with Nexvet.

January 2015

Winner of the Animal Pharm Award 2014 for Best Company in Asia/Australasia.

July 2014

Completion of the construction of the state-of-the-art, GMP-compliant biological manufacturing plant (Third Manufacturing Plant) in Koriyama, Japan.

July 2013

Completion of the construction of the new main administration building, a symbol of recovery in Koriyama, Japan, from the Great East Japan Earthquake of 2011. The building is an eco-friendly, open office building that uses natural energy.

July 2011

Establishment of the Tokyo Branch Office.

March 2011

Severe damage caused to ZENOAQ's head office in Koriyama by the Great East Japan Earthquake. The beginning of the road to recovery.


April 2009

Acquisition of Nippon Biologicals Inc., a company that develops and imports avian vaccines as an affiliate.

April 2009

Appointment of Dr. Kuniaki Fukui, former President of Nippon Zenyaku Kogyo Co., Ltd, as Chairman.
Appointment of Mr. Keiichi Takano to Dr. Fukui's previous role as President.

April, May, December 2008

Completion of the construction of new buildings of the Central Research Laboratory Animal Research Center in Koriyama, Japan.

December 2007

Business tie-up with IDEXX Laboratories K.K.

January 2005

Establishment of the Beijing Representative Office in China to target the Chinese and Korean markets.

February 2004

Business tie-up with Nippon Biologicals, Inc.

March 2003

Business tie-up with Zinpro Animal Nutrition Japan K.K.

June 2002

Commencement of import and sales of mineral salt blocks manufactured at Tianjin Zenyaku Animal Health Co., Ltd in China.

August 2001

Announcement of the corporate brand, ZENOAQ.

April 2001

Integration of the head office and 6 marketing subsidiaries throughout Japan as Nippon Zenyaku Kogyo Co., Ltd.
Set-up of sales system according to animal groups (Dairy Cattle, Beef Cattle, Swine, Avian and Companion Animal).

February 2001

Set-up of Tianjin Zenyaku Animal Health Co., Ltd. as a manufacturing plant in China.

January 2001

Merging of Merial Nippon Zenyaku Limited with Merial Japan Limited.
Nippon Zenyaku Kogyo undertakes a portion of the equity.


January 1999

Creation of the Avian Business Division.

May 1996

Celebration of the 50th year anniversary of Nippon Zenyaku Kogyo.

April 1996

Establishment of Rhone-Merieux Nippon Zenyaku Limited, a joint venture with Rhone Merieux (later changed to Merial Nippon Zenyaku Limited).

October 1989

Establishment of the Clinical Research Farm in Ono. This facility, together with the Central Research Laboratory, is GLP-compliant.

May 1988

Appointment of Mr. Kuniaki Fukui as President.

November 1983

Establishment of Kobayashi manufacturing plant in Kyushu, where the livestock industry had suddenly expanded.
The new plant focused on the production of KOEN®.

June 1982

Establishment of the Central Research Laboratory and a laboratory for specialized experiments involving large animals. The laboratory was completed on a scale never before seen by animal pharmaceutical makers of the time in Japan.

April 1976

Business tie-up with Fujisawa Pharmaceutical Co., Ltd.

March 1975

Completion of the construction of the new manufacturing plant in Koriyama (Asaka), Japan.

August 1972

Business tie-up with SmithKline and French Laboratories (SK&F). This was ZENOAQ's first business partnership with an overseas company. This began the importation and sale of SK&F's products, including vaccines and heartworm medications.

April 1971

Establishment of the Kushiro manufacturing plant in Hokkaido, the region with the largest demand for mineral salts.
Following a sudden increase in livestock populations in Hokkaido, the decision was made to expand production to meet future demand. As the necessity of salt and minerals became more widely recognized, new products, such as KOEN® M and KOEN® S, were launched.


March 1969

Establishment of the Hokkaido Shakunage Forum. In order to realize the company motto of being a company indispensable to the livestock industry, the Hokkaido Shakunage Forum, focused on uniting industry, government, and academia, was established. Following this inaugural event, shakunage forums were set up in Kanto, Kyushu, and more, spreading nationwide.

March 1962

Commencement of manufacturing of vial products.

January 1958

Establishment of a manufacturing plant for mineral salt blocks known as KOEN®.

December 1956

Establishment of an additional plant in Koriyama (Showa), Japan.

September 1955

Commencement of manufacturing of antibiotic formulations.

November 1953

The PR video "Cow-Targeting Parasites" was produced and released to promote the spread of new pharmaceuticals nationwide.

April 1953

Successful R&D of Neo Hexaron, a liver fluke parasiticide in Sadogashima.

May 1949

Company name changed to Nippon Zenyaku Kogyo Co., Ltd.

April 1948

Commencement of the manufacturing of veterinary pharmaceuticals following acceptance of an order from Fukushima Prefecture.
After receiving an order for Ringer's solution for horses, the company began production of osteomalacia pharmaceuticals, including OSM and OSM Strong.

May 1946

Establishment of Asahi Yakuhin Kogyo Co., Ltd, which would later be renamed Nippon Zenyaku Kogyo Co., LTD., a human pharmaceutical manufacturing company with a capital of 180,000 yen.
Commencement of manufacturing in Koriyama (Miyata), Japan.